Aclaris Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

• Aclaris Therapeutics, Inc. showed a decrease of -18.8% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
• This data is from Aclaris Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
• XBRL data for this metric is available from 2012 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2015: $8.47 million | Q2 2015: $9.85 million | Q3 2015: $25.42 million | Q1 2016: $13.13 million | Q2 2016: $31.82 million | Q3 2016: $17.80 million | Q4 2016: $30.17 million | Q1 2017: $23.68 million | Q2 2017: $32.71 million | Q3 2017: $60.06 million | Q4 2017: $20.20 million | Q1 2018: $54.88 million | Q3 2020: $23.64 million | Q1 2021: $35.27 million | Q2 2021: $113.45 million | Q3 2021: $53.60 million | Q1 2022: $36.34 million | Q2 2022: $68.26 million | Q3 2022: $61.65 million | Q1 2023: $44.72 million | Q2 2023: $31.15 million | Q3 2023: $39.04 million | Q1 2024: $35.84 million | Q2 2024: $22.83 million | Q3 2024: $47.65 million | Q1 2025: $30.36 million | Q2 2025: $25.40 million | Q3 2025: $25.26 million.
• Over the full 13 years of available data (2012 to 2025), Aclaris Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 4.8%.
• Historical annual values: Fiscal year 2025: $19.96 million | Fiscal year 2024: $24.57 million | Fiscal year 2023: $39.88 million | Fiscal year 2022: $45.28 million | Fiscal year 2021: $27.35 million | Fiscal year 2020: $22.06 million | Fiscal year 2019: $34.19 million | Fiscal year 2017: $20.20 million | Fiscal year 2016: $30.17 million | Fiscal year 2015: $9.85 million | Fiscal year 2014: $10.76 million | Fiscal year 2013: $9.59 million | Fiscal year 2012: $19.04 million.
• Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: August 9, 2026